Back to results
US 9,518,119 B2Granted
IL3Rα antibody conjugates and uses thereof
AssigneeStemline Therapeutics, Inc.
InventorIvan Bergstein
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeStemline Therapeutics, Inc.
InventorIvan Bergstein
Estimating the term…
The present invention provides antibodies that bind to the IL-3 receptor alpha subunit alpha (Il3Rα) chain, and compositions comprising such antibodies. The present invention provides methods for inhibiting or reducing an IL3Rα-expressing cell population, the methods comprising contacting a population of IL3Rα-expressing cells (e.g., cancer cells and/or cancer stem cells) with an antibody that binds to IL3Rα. The present invention also provides antibody conjugates comprising an antibody that binds to an IL3Rα chain linked to a cytotoxic agent or anticellular agent and compositions comprising such conjugates. The present invention also provides methods for preventing, treating and/or managing a disorder associated with IL3Rα-expressing cells (e.g., a hematological cancer), the methods comprising administering to a subject in need thereof an antibody that binds to IL3Rα.
A nucleic acid that encodes a single chain fragment variable (scFv) region of an antibody that binds CD123, wherein said nucleic acid comprises nucleotide sequences that encode the complementarity determining regions (CDRs) of the variable heavy (VH) domain and the variable light (VL) domain of said antibody, and wherein said CDRs comprise the VH domain CDR1 presented in SEQ ID NO:
A nucleic acid that encodes an anti-CD123 single chain fragment variable (scFv) antibody region, wherein said nucleic acid comprises SEQ ID NO:
A nucleic acid that encodes the variable heavy (VH) domain of monoclonal antibody 26292, wherein said VH domain comprises SEQ ID NO:
A nucleic acid that encodes the variable light (VL) domain of monoclonal antibody 26292, wherein said VL domain comprises SEQ ID NO:
Dependencies are inferred from the claim text.